Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Plasma Protease C1-Inhibitor Market Grown from 2024 to 2025?

The market for plasma protease c1-inhibitor has seen swift expansion in recent years. The market is expected to surge from $3.37 billion in 2024 to $3.85 billion in 2025 with a compound annual growth rate (CAGR) of 14.4%. The outstanding growth in the past period is due to factors such as the rising prevalence of hereditary angioedema, increased understanding of rare genetic disorders, a heightened demand for plasma-derived therapeutics, escalating diagnostic rates of C1-inhibitor deficiency, and a growing acceptance of replacement therapies in emergency care situations.

What Growth Rate Is Anticipated for the Plasma Protease C1-Inhibitor Market in the Coming Years?

The market for the plasma protease C1-inhibitor is projected to experience an accelerated progression in the coming years. By 2029, the market is anticipated to reach $6.53 billion, multiplying at a compound annual growth rate (CAGR) of 14.1%. This significant surge during the forecast period is attributable to the amplified focus on customized medicines, rising pipeline developments for C1-Inhibitor therapies that are in the clinical trial stage, growing demand for preventive treatment options, escalating availability of home-based C1-inhibitor infusion therapies, and increasing awareness regarding C1-inhibitor deficiencies in surgical scenarios. The forecast period sees key trends such as the development of orphan drug applications, generation of low-immunogenic variants, incorporation of genomic tools, integration into telemedicine platforms, and innovative advancements in long-acting C1-inhibitors.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24659&type=smp

Who Are the Leading Companies in the Plasma Protease C1-Inhibitor Market?

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V., Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, Lev Pharmaceuticals.

What Are the Key Drivers of the Plasma Protease C1-Inhibitor Market?

Increasing investments in the treatment of rare diseases is projected to fuel the expansion of the plasma protease C1-inhibitor market in the near future. Rare diseases, which typically affect less than one in 2000 people, are health conditions that majorly impact a minor segment of the population. These diseases can be progressive, chronic and could potentially threaten life or cause disability. The escalating investment in this area is a byproduct of a rising acknowledgment of unmet healthcare needs and the enticing prospect of high return on investment via regulatory inducements such as market exclusivity, orphan drug status and reduced costs of development. This investment further facilitates the evolution of plasma protease C1-inhibitors by supporting research and fostering innovation to treat hereditary angioedema and other such rare diseases where severe symptoms are caused by a deficiency of C1-inhibitor. This, in turn, speeds up the provision of specialized therapies. For example, Global Genes, a nonprofit organization based in the US, reported that in April 2024, companies working on drugs for rare diseases amassed $7.1 billion in the first quarter, which is a huge 307% increase over the $1.8 billion collected during the equivalent period in 2023. Accordingly, the escalating investment in treating rare diseases is propelling the growth of the plasma protease C1-inhibitor market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24659&type=smp

What Are the Key Market Segments in the Plasma Protease C1-Inhibitor Industry?

The plasma protease c1-inhibitor market covered in this report is segmented –

1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist

2) By Dosage Form: Lyphophlised, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor

2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor

3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor

4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor

5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist

What Are the Latest Trends in the Plasma Protease C1-Inhibitor Market?

Leading entities in the plasma protease C1-inhibitor market are concentrating on the creation of progressive products, such as injectable prescribed drugs, in order to provide swift, efficient relief for hereditary angioedema and to enhance the results of the treatment. These injectable prescribed drugs are those which are implemented via injection and they function by reinstating or substituting plasma protease C1-inhibitors in order to manage inflammation and ward off attacks of swelling. For instance, in December 2022, an injectable remedy approved by the FDA known as CINRYZE was introduced in India by Takeda Pharmaceutical Company Limited, a pharmaceutical enterprise based out of Japan. CINRYZE is the inaugural C1 esterase inhibitor for prophylactic treatment designed for patients who are six years and above. This injectable preparation efficaciously mitigates the intensity, duration and regularity of hereditary angioedema (HAE) attacks by escalating levels of C1-INH in the plasma, which aids in halting excessive production of bradykinin and regulating the swelling associated with the sickness.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/plasma-protease-c1-inhibitor-global-market-report

What Are the Key Regional Markets in the Plasma Protease C1-Inhibitor Industry?

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24659

This Report Delivers Insight On:

1. How big is the plasma protease c1-inhibitor market, and how is it changing globally?

2. Who are the major companies in the plasma protease c1-inhibitor market, and how are they performing?

3. What are the key opportunities and risks in the plasma protease c1-inhibitor market right now?

4. Which products or customer segments are growing the most in the plasma protease c1-inhibitor market?

5. What factors are helping or slowing down the growth of the plasma protease c1-inhibitor market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model